Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?

Eur J Cancer. 2020 Oct:138:169-171. doi: 10.1016/j.ejca.2020.07.028. Epub 2020 Sep 2.

Authors

Katharina C Kähler¹, Katerina Kosova², Ann-Sophie Bohne², Sefan Schreiber², Axel Hauschild²

Affiliations

¹ University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Department of Dermatology, Kiel, Germany. Electronic address: kkaehler@dermatology.uni-kiel.de.
² University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Department of Dermatology, Kiel, Germany.

PMID: 32890812
DOI: 10.1016/j.ejca.2020.07.028

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / adverse effects*
Clinical Trials as Topic
Diabetes Mellitus, Type 1 / chemically induced*
Diabetes Mellitus, Type 1 / diagnosis
Drug Administration Schedule
Female
Humans
Immune Checkpoint Inhibitors / administration & dosage
Immune Checkpoint Inhibitors / adverse effects*
Male
Melanoma / drug therapy*
Melanoma / immunology
Risk Assessment
Risk Factors
Skin Neoplasms / drug therapy*
Skin Neoplasms / immunology
Time Factors
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
pembrolizumab